12 JulyGeraldine MacGibbon Senior Therapeutic Group Manager PHARMAC PO Box

First Page		Document Content
Date: 2016-07-11 21:31:12 Clinical medicine Breakthrough therapy Medicine Antineoplastic drugs Pharmacology Monoclonal antibodies Bristol-Myers Squibb Nivolumab Melanoma Programmed cell death protein 1 Pembrolizumab Raltegravir		12 JulyGeraldine MacGibbon Senior Therapeutic Group Manager PHARMAC PO Box Add to Reading List Source URL: www.nzma.org.nz Download Document from Source Website File Size: 204,40 KB Share Document on Facebook

	A Day in Life at BMS Welcome to A Day in Life at BMS where you will meet leaders from our R&D organization and learn more about research and development at Bristol-Myers Squibb, as well as network with our scientists. To DocID: 1vrK6 - View Document
	NoIN THE Supreme Court of the United States BRISTOL-MYERS SQUIBB COMPANY, PETITIONER, DocID: 1tuCc - View Document
	Bristol-Myers Squibb Co. v. Superior Court of Cal., San Francisco Cty) DocID: 1tut4 - View Document
	September 2003 USA Bristol-Myers Squibb Medical Imaging DocID: 1sKnx - View Document
	May 2003 Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road N. Billerica, Massachusetts 01862 DocID: 1sC8T - View Document